Product Design, Manufacturing & Innovation Resources

Dernières publications et brevets en oncologie moléculaire

Publications en oncologie moléculaire Brevets

Astuce : suite à la sélection ci-dessous, vous pouvez rechercher et filtrer nos 2 bases de données complètes :

> outil de recherche de publications gratuit < par auteur, sujet, mots-clés, date ou revue.

> outil gratuit de recherche de brevets < pour les brevets en anglais de l'Office européen des brevets.

Oncologie moléculaire
L'oncologie moléculaire exploite les technologies de pointe pour innover dans le diagnostic et le traitement du cancer grâce à des connaissances génétiques et biochimiques.

L'oncologie moléculaire étudie les altérations génétiques, épigénétiques et biochimiques à l'origine de l'initiation, de la progression et de la résistance aux traitements du cancer. Ce domaine intègre le séquençage à haut débit, le diagnostic moléculaire et les thérapies ciblées pour élucider les voies oncogéniques, l'inactivation des gènes suppresseurs de tumeurs et les interactions avec le microenvironnement tumoral. Les progrès en matière de profilage moléculaire, de découverte de biomarqueurs et de médecine de précision redéfinissent la classification du cancer et les stratégies thérapeutiques. Cette compilation présente les publications les plus récentes, évaluées par les pairs, ainsi que les innovations brevetées, reflétant la recherche de pointe sur les oncogènes, la transduction du signal, les cellules souches cancéreuses, l'immunomodulation et les techniques d'imagerie moléculaire essentielles à l'oncologie translationnelle et aux applications cliniques.

Il s'agit de notre dernière sélection de publications et de brevets mondiaux en anglais sur l'oncologie moléculaire, parmi de nombreuses revues scientifiques en ligne, classées et axées sur l'oncogène, la suppression des tumeurs, la voie de transduction des signaux, la génomique du cancer, l'épigénétique dans le cancer, le biomarqueur moléculaire, la thérapie ciblée du cancer, la signalisation cellulaire du cancer, la mutation de l'ADN, les microARN en oncologie, les cellules souches du cancer, la régulation de l'apoptose, microenvironnement tumoral, immunothérapie du cancer, profil d'expression génétique, aberration chromosomique, diagnostic moléculaire, protéomique du cancer, voie oncogène, métastase du cancer, mécanismes moléculaires de la cancérogenèse, hétérogénéité tumorale, épigénomique du cancer, virus oncogène, médicament moléculaire ciblé, transcriptomique du cancer, mécanisme de réparation de l'ADN, pharmacogénomique du cancer et pathologie moléculaire du cancer.

Eutrema japonica leaf alcohol extract and use thereof in treatment of cancer stem cell-related cancer

Patent published on the 2026-10-01 in WO under Ref WO2026200822 by TAIWAN FLOWER BIOTECHNOLOGY CO LTD [CN] (Wang Lu-hai [cn], Huang A-chih [cn], Huang Shi-jie [cn], Lee Yu Ting [cn])

Abstract: Disclosed is use of a pharmaceutical composition in the manufacture of a medicament for treating a cancer stem cell-related cancer, inhibiting the recurrence or metastasis of cancer stem cells after cancer tumor resection, or inhibiting tumor-associated angiogenesis. The pharmaceutical composition comprises an Eutrema japonica leaf alcohol extract. The cancer stem cell-related cancer comprises triple-negative breast cancer, ovarian cancer, prostate cancer, lung cancer, or oral cancer.[...]


Our summary: Eutrema japonica leaf alcohol extract is used in a pharmaceutical composition to treat cancer stem cell-related cancers. It aims to inhibit recurrence or metastasis of cancer stem cells post-tumor resection. The extract targets various cancers, including triple-negative breast cancer and ovarian cancer.

Eutrema japonica, cancer stem cells, pharmaceutical composition, angiogenesis

Patent

Epitope selection methods

Patent published on the 2026-10-01 in WO under Ref WO2026202772 by BIONTECH SE [DE] (Sahin Ugur [de], Lang Maren [de], Okandan Aylin [de], Vormehr Mathias [de])

Abstract: Presented herein are methods and systems that allow for identification and selection of antigens, e.g., for cancer immunotherapy, such as for inclusion in personalized cancer vaccines (PCVs), use in T-cell therapies, T-cell receptor (TCR)-based therapies, etc.[...]


Our summary: This content discusses methods for identifying and selecting antigens for cancer immunotherapy. It highlights their application in personalized cancer vaccines and T-cell therapies. The focus is on improving therapeutic outcomes through effective epitope selection.

epitope selection, cancer immunotherapy, personalized cancer vaccines, T-cell therapies

Patent

Tropomyosin receptor kinase a (trka) inhibitors and uses thereof

Patent published on the 2026-10-01 in WO under Ref WO2026199075 by UNIV BRITISH COLUMBIA [CA] (Page Brent [ca], Iliev Petar Ilianov [ca], Mccutcheon Conall Robert [ca])

Abstract: Provided herein are compounds of Formula I-III for use in modulating tropomyosin receptor kinase A (TrkA) activity. In particular, the compounds as described herein may have TrkA inhibitory activity. Furthermore, the compounds as described herein may also have multi-kinase inhibitory activity of Janus kinase 2 (JAK2) and/or Proto-Oncogene Tyrosine-Protein Kinase Src (SRC). The compounds as described herein may useful for the treatment of cancer, osteoarthritis (OA), rheumatoid arthritis (RA), in[...]


Our summary: The document discusses compounds that inhibit tropomyosin receptor kinase A (TrkA) and their potential therapeutic uses. These compounds may also inhibit Janus kinase 2 (JAK2) and Src kinases. Applications include treating cancer, osteoarthritis, rheumatoid arthritis, and managing pain and inflammation.

TrkA inhibitors, multi-kinase activity, cancer treatment, inflammation management

Patent

Targeting serotonin transporter (sert) for cancer immunotherapy

Patent published on the 2026-10-01 in WO under Ref WO2026207149 by UNIV CALIFORNIA [US] (Li Bo [us], Yang Lili [us])

Abstract: The invention provides methods for the induction of the serotonin transporter (SERT) gene in solid tumor-infiltrating cytotoxic CD8 T cells. In solid tumors, CD8 T cells secrete serotonin, which stimulates their antitumor reactivities, while SERT functions as a negative regulator by depleting intratumoral serotonin. Discoveries presented herein show that the inhibition of SERT using clinically approved selective serotonin reuptake inhibitors (SSRIs), a popular class of antidepressants, can signi[...]


Our summary: The invention targets the serotonin transporter (SERT) to enhance cancer immunotherapy. Inhibition of SERT in CD8 T cells boosts their antitumor activity. SSRIs show therapeutic synergy with anti-PD-1 therapy and correlate with patient survival in cancers.

serotonin transporter, cancer immunotherapy, CD8 T cells, SSRIs

Patent

Multistage stimuli-responsive nanoparticle platform for intracellular delivery of biologics and drug conjugates thereof

Patent published on the 2026-09-24 in WO under Ref WO2026198863 by LIU QIYONG PETER [US] (Liu Qiyong [us])

Abstract: A multistage, stimuli-responsive nanoparticle platform (TRIDENT) for targeted intracellular delivery of biologic therapeutics is disclosed. The platform comprises an amine-functionalized crosslinked dextran shell on an iron oxide core, with a tunable hydrodynamic diameter of 15-60 nm designed to exceed the renal filtration threshold while enabling tumor accumulation via the EPR effect. Therapeutic payloads — including nanobodies, antibody fragments, peptides, enzymes, and protein-drug conjugat[...]


Our summary: The TRIDENT platform is a multistage, stimuli-responsive nanoparticle system designed for targeted intracellular delivery of biologics. It features a crosslinked dextran shell on an iron oxide core, allowing for tumor accumulation while overcoming renal filtration. The platform enables cytosolic release of therapeutic payloads and supports treatment of heterogeneous tumors.

nanoparticles, intracellular delivery, stimuli-responsive, drug conjugates

Patent

Method for increasing salt tolerance in a crop plant

Patent published on the 2026-09-03 in WO under Ref WO2026181077 by THE DEAD SEA ARAVA SCIENCE CENTER DSASC [IL] (Barak Simon [il], Winters Gidon [il])

Abstract: The invention provides methods for identifying genes associated with plant stress tolerance and producing stress-tolerant crop plants by genome editing. Gene expression profiles under a selected stress are compared between a stress-tolerant plant and a closely related stress-sensitive plant to identify and prioritize candidate regulatory genes, including genes showing constitutively low and/or downregulated "stress-ready" expression in the tolerant plant. Selected homologs or orthologs are edite[...]


Our summary: The method identifies genes linked to salt tolerance in crops. It uses gene expression profiles to find candidate regulatory genes. Genome editing techniques like CRISPR are employed to create stress-tolerant crop plants.

genome editing, stress tolerance, gene expression, CRISPR

Patent

rethinking comprehensive screening in the era of AI

Published on 2026-08-13 by David A. Shaywitz, Nathan D. Price, Daniel K. Sodickson @NATURE npj

Abstract: npj Digital Medicine, Published online: 13 August 2026; doi:10.1038/s41746-026-03106-2Applying advanced measurement technologies proactively in asymptomatic populations predictably yields false positives, as a consequence of Bayes’ Theorem. Yet the same Bayesian arithmetic suggests a remedy: adding context. Serial and multimodal measurements, integrated using context-aware AI that prioritizes within-person change over population norms, can reduce false positive rates while preserving sensitivi[...]


Our summary: The article discusses the impact of advanced measurement technologies on screening asymptomatic populations. It highlights the role of context-aware AI in reducing false positives through serial and multimodal measurements. Challenges such as cost, anxiety, liability, and equity in implementing these technologies are also addressed.

screening, AI, Bayesian, diagnostics

Publication

Glioblastoma-Derived Extracellular Vesicles Modulate &gamma;&delta; T Lymphocytes Through a MIC-Dependent Mechanism

Published on 2026-02-03 by Micaela Rosato, Paula Saibene Vlez, Alejandra Infante Cruz, Matas A. Pibuel, Federico Fuentes, Mnica Vermeulen, Juan Iturrizaga, Pablo E. Espil, Silvia Berner, Gabriela V. Salamone, Carolina C. Jancic @MDPI

Abstract: Glioblastoma (GBM) is the most aggressive and common primary brain tumor, with a median survival of less than a year after diagnosis. &amp;gamma;&amp;delta; T lymphocytes are immune cells that can migrate to tumors and induce malignant cells&amp;rsquo; apoptosis. Our previous in silico studies showed that higher &amp;gamma;&amp;delta; T-cell infiltration in GBM correlates with better patient survival, and in vitro experiments showed that GMB supernatants promote an antitumora[...]


Our summary: Glioblastoma-derived extracellular vesicles (EVs) modulate gamma delta T lymphocytes through a MIC-dependent mechanism. Increased CD69 expression, cytotoxicity, and cytokine production in T cells were observed following EV interaction. These findings offer insights for targeted immunotherapy development in glioblastoma patients.

Extracellular vesicles, Glioblastoma, Gamma delta T lymphocytes, Immunotherapy

Publication

Sujets abordés : Oncologie moléculaire, altérations génétiques, altérations épigénétiques, altérations biochimiques, séquençage à haut débit, diagnostics moléculaires, thérapeutiques ciblées, voies oncogéniques, gènes suppresseurs de tumeurs, microenvironnement tumoral, découverte de biomarqueurs, médecine de précision, classification des cancers, immunomodulation, imagerie moléculaire, oncologie translationnelle, applications cliniques, publications évaluées par les pairs, innovations brevetées ISO 15189, ISO 9001, ISO/IEC 17025, lignes directrices du CLSI et ASTM E2876.

Contexte historique

1965
1970
1980
1980
1990
1960
1969
1976-05-28
1980
1990

(si la date est inconnue ou non pertinente, par exemple « mécanique des fluides », une estimation arrondie de son émergence notable est fournie)

10e année anniversaire

Les images en pleine résolution et les téléchargements sont uniquement disponibles, et 100% gratuits, pour les membres inscrits.